Big Pharma has patented the exclusive rights to a cancer cure using cannabis, preventing others from using THC and CBD to treat the disease.
British company, GW Pharmaceuticals, had previously developed cannabis-based drugs for multiple sclerosis and epilepsy. Now, they hold the rights to treat cancer.
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
Rxleaf.com reports: That’s right. Big Pharma now holds the patent for cancer treatment using cannabis. Let. That. Sink. In. For. A. Moment.
Balenciaga Pedo-gate Blown WIDE OPEN
Klaus Schwab and George Soros Declare China Must Lead New World Order
Klaus Schwab: ‘God Is Dead’ and the WEF is ‘Acquiring Divine Powers’
‘Passion of the Christ’ Star Claims Hollywood Elite Are Trafficking Children For Adrenochrome
Bill Gates Tells World Leaders ‘Death Panels’ Will Soon Be Required
Justin Bieber: Facial Paralysis Is ‘Punishment’ For Exposing Illuminati Pedophilia
Spanish Royalty Expose Who Really Killed Princess Diana
‘Controlled Opposition’: Dave Chappelle’s Family Say He Was Killed and Cloned by the Illuminati
Michael Jackson Was Murdered for Saying SAME Things As Kanye 13 Years Ago
Error 403: The request cannot be completed because you have exceeded your quota..
Domain code: youtube.quota
Reason code: quotaExceeded
In 2009, GW went forward with a patent application, alongside collaborator Otsuka Pharmaceutical. At the end of September, GW announced that they had received a Notice of Allowance from the U.S. Patent Office to go forward with production of their cannabis-based cancer treatment, Sativex.
Numerous studies have shown that cannabis can be used to treat cancer by eradicating cancer cells and stopping metastasis, in most types of cancer. The latest GW drug will harness the power of THC and CBD to treat gliomas, which are a rare form of brain cancer.
The now-patented pharmaceutical uses a ratio of THC and CBD ranging from 1:1 to 1:20 (THC:CBD) to “reduce cell viability, inhibit cell growth or reduce tumor volume”, according to the company. It is interesting to note that GW’s treatment, Sativex, grew out of a long history of pre-clinical trials and anecdotal evidence that show the use of cannabis and cannabis-based products for tumor reduction.
The company went ahead with clinical trials in August 2018 to test the efficacy of Sativex. This trial will look at efficacy of Sativex when combined with more traditional mainstream cancer treatments. Sativex and the chemotherapy drug, temozolomide, has been administered to 20 patients with recurrent glioblastoma multiforme (GBM). This is a rare and very deadly type of brain cancer.
The original patent application was sent in 2009, but has been subsequently changed to accommodate FDA requirements. Changes would include specifics like THC and CBD ratios in the medication, as well as the forms of cancer that Sativex may be able to treat.
What Does This Mean for Cancer Research?
On the positive side, the patent recognizes the value of cannabis for cancer treatments, and not just as a way to counteract the effects of chemotherapy and radiation. Cannabis’ efficacy for killing cancer cells must now be recognized on a federal level. This also allows for more options for cancer patients in choosing their treatments.
It’s a potentially exciting time for cannabis research! Look out for more patents, more clinical trials, and even more cannabis-based medications hitting the market. Keep pushing for access to whole plant medicine.
Latest posts by Sean Adl-Tabatabai (see all)
- CDC: ‘1.1 Million Americans Have Died Due to COVID Vaccines’ – Stunning Admission - December 4, 2022
- Trudeau Regime Ordered Disabled Veteran To Be ‘EUTHANIZED’ Because She Cost the State ‘Too Much Money’ - December 4, 2022
- “I’m Coming for You”: James Woods Vows To Sue DNC Into Oblivion for Illegal Censorship of Americans - December 4, 2022